Abstract | OBJECTIVE: METHODS: Patients were randomized double-blind to zofenopril (n=719) or placebo (n=699) for 6 weeks. The primary end point was the effect of treatment on the 6-week combined occurrence of death and severe congestive heart failure. The secondary end point was the 1-year mortality rate. RESULTS: Of the 1418 patients included in this post-hoc analysis, 686 (48.3%) had MS. After 6 weeks of treatment zofenopril significantly reduced the incidence of all-cause death and severe congestive failure (risk reduction: 69%, 95% CI: 7-78; 2p=0.002) in MS+ patients. This was the case for 1-year mortality, too (29%, 95% CI: 4-41; 2p=0.048). Zofenopril was effective also in MS- patients but the amount of relative risk reduction was less than in MS+ for both the primary (-11%; 2p=0.61) and secondary endpoint (-19%; 2p=0.025). CONCLUSIONS: Results of this post-hoc analysis of the SMILE Study demonstrate the striking benefit of early administration of zofenopril in MS+ patients with acute anterior myocardial infarction.
|
Authors | Claudio Borghi, Arrigo F G Cicero, Ettore Ambrosioni |
Journal | Vascular health and risk management
(Vasc Health Risk Manag)
Vol. 4
Issue 3
Pg. 665-71
( 2008)
ISSN: 1176-6344 [Print] New Zealand |
PMID | 18827916
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- zofenopril
- Captopril
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(administration & dosage, therapeutic use)
- Blood Pressure
(drug effects)
- Captopril
(administration & dosage, analogs & derivatives, therapeutic use)
- Comorbidity
- Female
- Heart Failure
(epidemiology)
- Humans
- Incidence
- Male
- Metabolic Syndrome
(drug therapy, epidemiology)
- Middle Aged
- Myocardial Infarction
(drug therapy, epidemiology)
|